12 November 2021 | News
To support expanded discovery chemistry and in-vitro ADME services
Image Credit: Shutterstock
Bengaluru-based contract research organisation (CRO) Jubilant Biosys has announced the expansion of its facilities to support its discovery chemistry and in-vitro ADME (absorption, distribution, metabolism, and excretion) Service offerings.
Jubilant Biosys provides services for Turning Point Therapeutics for multiple small molecule oncology research programmes. Turning Point is a precision oncology company developing next-generation therapies that target genetic drivers of cancer.
Services for Turning Point Therapeutics will be conducted out of the newly built state-of-the-art Chemistry Innovation Research Center (CIRC) in Greater Noida.
The CIRC has an initial capacity of 500 full-time equivalents (FTEs) enabling higher operational performance for discovery chemistry services and also rapid turn-around of in-vitro ADME data for client projects.